Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$79.78
+$1.03 · +1.31%
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Previous close
$79.78
+$1.03 · +1.31%
Regular session · ET · Market data may be delayed.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Day range
Current $79.78
52-week range
Current $79.78
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
79
Undervalued
Sentiment
66
Bullish
Risk
31
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Day range
Current $79.78
52-week range
Current $79.78
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$86.40
8.30% upsidePrice history unavailable
High $99.00Average $86.40Low $71.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI103.96M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM94.52M0.12%78.74B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB75.35M0.04%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK43.39M0.09%44.7B USD0.05%$344.74+1.22%
iShares Russell 2000 Growth ETFIWO33.23M0.24%13.92B USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS25.22M0.07%33.87B USD0.31%$78.35+0.32%
Vanguard Russell 2000 ETFVTWO19.16M0.10%18B USD0.06%$112.66+0.50%
Dimensional - US Core Equity 2 ETFDFAC12.32M0.01%88.6B USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWODimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
